Quick Answer
Hyaluronic Skin Aging Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: In accordance with EMA Committee for Advanced Therapies (EMA-CAT) recommendations (Guideline on Human Cell-Based Medicinal Products, 2015, section 2.2.4a), this approach qualifies as a “technique, since the processing does not alter the biological characteristics, physiological functions, or structural properties of the cells.
Key Takeaways
- 01In accordance with EMA Committee for Advanced Therapies (EMA-CAT) recommendations (Guideline on Human Cell-Based Medicinal Products, 2015, section 2.2.4a), this approach qualifies as a “technique, since the processing does not alter the biological characteristics, physiological functions, or structural properties of the cells. [Gentile Pietro (2026)]
- 0220 patients with mild to moderate dermal thinning, reduced elasticity, and wrinkles were assigned to the study group (SG) and treated with Am-FBs (A–C). [Gentile Pietro (2026)]
- 03The Risk Evaluation and Mitigation Strategies (REMSs) incorporating Elements to Assure Safe Use (ETASU) were applied in Am-FBs and HA-based skin booster treatments, significantly reducing safety-related risks. [Gentile Pietro (2026)]
- 04, , , The natural aging process leads to the degradation of the dermal extracellular matrix (ECM), decreased fibroblast activity, and a loss of skin elasticity.Traditional cosmetic procedures, such as hyaluronic acid (HA)-based skin boosters, provide temporary benefits, but autologous cell-based therapies offer a biologically driven regenerative approach. [Gentile Pietro (2026)]
The current Migaku evidence database contains 2 reusable source documents for Hyaluronic Skin Aging Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- In accordance with EMA Committee for Advanced Therapies (EMA-CAT) recommendations (Guideline on Human Cell-Based Medicinal Products, 2015, section 2.2.4a), this approach qualifies as a “technique, since the processing does not alter the biological characteristics, physiological functions, or structural properties of the cells. [Gentile Pietro (2026); evidence level 2]
- 20 patients with mild to moderate dermal thinning, reduced elasticity, and wrinkles were assigned to the study group (SG) and treated with Am-FBs (A–C). [Gentile Pietro (2026); evidence level 2]
- The Risk Evaluation and Mitigation Strategies (REMSs) incorporating Elements to Assure Safe Use (ETASU) were applied in Am-FBs and HA-based skin booster treatments, significantly reducing safety-related risks. [Gentile Pietro (2026); evidence level 2]
- , , , The natural aging process leads to the degradation of the dermal extracellular matrix (ECM), decreased fibroblast activity, and a loss of skin elasticity.Traditional cosmetic procedures, such as hyaluronic acid (HA)-based skin boosters, provide temporary benefits, but autologous cell-based therapies offer a biologically driven regenerative approach. [Gentile Pietro (2026); evidence level 2]
- Collagen, along with antioxidants such as curcumin and glutathione, have gained increased utilization/awareness in recent years, providing dermal health benefits especially in women who experience declining or loss of estrogen with aging. [Arbex Priscila (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources